FDA expectations on Drug-Induced Liver Injury (DILI) are having an important impact on the pharmaceutical industry in assessing the potential for a drug to cause severe liver injury.

This webinar will discuss hepatic drug toxicity, FDA’s guidance on DILI and demonstrate an approach that specifically targets real time identification of abnormal hepatic triggers and subsequent medical monitoring of patients.

Topics to be covered:

Expert Panelists:

• FDA Guidance and DILI: Key Implications

• Diagnosis of Drug Induced Liver Injury

• What is Hy’s Law?

• Monitoring and pre-existent liver disease

• How to detect DILI in real-time

• How to manage a potential DILI case